# GATE5_PREAUTHORIZATION_FINAL_CHECK_V1

## Final Status: `GATE5_AUTHORIZATION_REQUIRES_SEMANTIC_FIX`

This preauthorization audit halts the commencement of the Full Gate 5 execution due to critical issues regarding semantic polarity in the Relationship Grounding logic, as well as necessary corrections in authority taxonomies and historical protocol alignment.

---

### CHECK 1: POS-02 PROPOSITION / EXPECTED SEMANTICS
- **Status: FAILED RECONCILIATION**
- POS-02 was historically intended to test the retrieval of a positive interaction statement. The amended FDA evidence supports a **bounded negative** statement ("No clinically significant pharmacokinetic drug-drug interactions have been observed"). This fundamentally alters the semantic outcome expected for POS-02. The experiment protocol must formally establish whether a bounded negative finding satisfies the POS-02 requirements.

### CHECK 2: RELATION POLARITY
- **Status: FAILED (Critical V2 Logic Flaw)**
- Independent polarity testing revealed that `RelationshipGroundingValidatorV2` extracts the relation `INTERACTS_WITH` from the FDA's negative text simply because the word "interaction" appears. 
- Consequently, the validator evaluates the false positive statement *"Statin interacts with aspirin"* as `SUPPORTED` based on the FDA evidence that explicitly denies it. 
- The V2 regex logic does not correctly distinguish `POSITIVE_RELATION` from `NEGATED_RELATION` unless exact phrasings like "does not interact" are used. It completely misses the polarity of complex bounded denials (e.g., "no clinically significant... interactions").

### CHECK 3: SCOPE / QUALIFICATION OF EVIDENCE
- The FDA source supports a bounded denial: *"No clinically significant pharmacokinetic interaction observed."*
- It does not make a sweeping claim that *"Statin-aspirin interaction does not exist."*
- The current LLM generation phase must be instructed to preserve these nuances, which requires the underlying RAG system to correctly pass the semantic polarity through the grounding gate first.

### CHECK 4: ENTITY ALIGNMENT
- The `RelationshipGroundingValidatorV2` explicitly finds both `statin` and `aspirin` via regex mapping. It does not perform true class-to-instance pharmacological mapping, relying entirely on the parenthetical `(a statin)` in the FDA text to achieve alignment.

### CHECK 5: SOURCE AUTHORITY CLASSIFICATION
- **Status: FAILED TAXONOMY**
- The FDA label was incorrectly labeled as `tier_1_peer_reviewed`. It must be reclassified to an appropriate regulatory label (e.g., `tier_1_regulatory`) while keeping its authority score at `1.0`.

### CHECK 6: POS-02 EXPECTED OUTCOME RECONCILIATION
- The expectation for POS-02 has shifted from proving a positive interaction to answering an interaction query with a bounded negative finding. These are not equivalent replacements, and the protocol must formally document this shift.

### CHECK 7: HISTORICAL TEST FIXTURE CONTAMINATION
- `update_cases.py` still contains hardcoded mappings referencing `("POS-02", "statin interacts with aspirin", "doc_pos02")`. This historical synthetic fixture definition must be sanitized to ensure no contamination bleeds into the actual Gate 5 runtime via stale cached data or legacy case metadata.

---

### REQUIRED ACTIONS BEFORE FULL GATE 5

1. **Fix Relation Polarity in V2**: Update `RelationshipGroundingValidatorV2` to correctly detect negated semantic scopes, especially bounded denials commonly found in FDA labels (e.g., "no... interactions").
2. **Re-classify Source Authority**: Update `manifest.json` to categorize the FDA label correctly (e.g., `tier_1_regulatory`).
3. **Reconcile POS-02 Semantic Outcome**: Formally update the expected outcome of POS-02 in the test matrices to expect a Bounded Negative finding rather than a positive interaction.
4. **Sanitize Historical Fixtures**: Remove all references to the synthetic `doc_pos02` "statin interacts with aspirin" from the codebase and experiment scripts.
